The stock of CVS Health Corp (CVS) has gone down by -3.68% for the week, with a -15.42% drop in the past month and a -7.97% drop in the past quarter. The volatility ratio for the week is 1.50%, and the volatility levels for the past 30 days are 2.03% for CVS. The simple moving average for the past 20 days is -6.21% for CVS’s stock, with a -7.60% simple moving average for the past 200 days.
Is It Worth Investing in CVS Health Corp (NYSE: CVS) Right Now?
The price-to-earnings ratio for CVS Health Corp (NYSE: CVS) is 10.39x, which is above its average ratio. Moreover, the 36-month beta value for CVS is 0.55. Analysts have varying opinions on the stock, with 10 analysts rating it as a “buy,” 5 as “overweight,” 9 as “hold,” and 0 as “sell.”
The public float for CVS is 1.26B and currently, short sellers hold a 1.43% of that float. On April 29, 2024, CVS’s average trading volume was 9.45M shares.
CVS) stock’s latest price update
The stock of CVS Health Corp (NYSE: CVS) has decreased by -0.22 when compared to last closing price of 67.33. Despite this, the company has experienced a -3.68% fall in its stock price over the last five trading sessions. The Motley Fool reported 2024-04-27 that CVS Health is facing multiple issues, including lower coronavirus-related revenue. However, the company still has a business that seems built to last.
Analysts’ Opinion of CVS
Many brokerage firms have already submitted their reports for CVS stocks, with Barclays repeating the rating for CVS by listing it as a “Equal Weight.” The predicted price for CVS in the upcoming period, according to Barclays is $78 based on the research report published on March 06, 2024 of the current year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see CVS reach a price target of $88. The rating they have provided for CVS stocks is “Outperform” according to the report published on February 26th, 2024.
HSBC Securities gave a rating of “Buy” to CVS, setting the target price at $94 in the report published on December 22nd of the previous year.
CVS Trading at -9.87% from the 50-Day Moving Average
After a stumble in the market that brought CVS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.30% of loss for the given period.
Volatility was left at 2.03%, however, over the last 30 days, the volatility rate increased by 1.50%, as shares sank -15.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.08% lower at present.
During the last 5 trading sessions, CVS fell by -3.68%, which changed the moving average for the period of 200-days by -4.67% in comparison to the 20-day moving average, which settled at $71.00. In addition, CVS Health Corp saw -14.92% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CVS starting from Shah Prem S, who sale 29,473 shares at the price of $76.95 back on Feb 16 ’24. After this action, Shah Prem S now owns 39,765 shares of CVS Health Corp, valued at $2,267,947 using the latest closing price.
LUDWIG EDWARD J, the Director of CVS Health Corp, purchase 2,000 shares at $70.47 during a trade that took place back on Nov 03 ’23, which means that LUDWIG EDWARD J is holding 20,630 shares at $140,930 based on the most recent closing price.
Stock Fundamentals for CVS
Current profitability levels for the company are sitting at:
- 0.04 for the present operating margin
- -0.03 for the gross margin
The net margin for CVS Health Corp stands at 0.02. The total capital return value is set at 0.08. Equity return is now at value 11.32, with 3.38 for asset returns.
Based on CVS Health Corp (CVS), the company’s capital structure generated 0.51 points at debt to capital in total, while cash flow to debt ratio is standing at 0.17. The debt to equity ratio resting at 1.04. The interest coverage ratio of the stock is 5.17.
Currently, EBITDA for the company is 19.05 billion with net debt to EBITDA at 3.98. When we switch over and look at the enterprise to sales, we see a ratio of 0.44. The receivables turnover for the company is 10.16for trailing twelve months and the total asset turnover is 1.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.86.
Conclusion
To wrap up, the performance of CVS Health Corp (CVS) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
